SLC5A2 and heart failure: Finally, the percentage of individuals receiving drugs included in the European heart failure guidelines with a demonstrated effect upon mortality (such as ARNIs and sodium-glucose cotransporter 2 inhibitors) [20] was low, since their use was not stated in the existing guidelines at the beginning of the study [49].